Novavax vaccine trial shows 90% efficacy against Covid-19


Novavax’s Covid-19 vaccine was 90% effective in late-stage trials conducted in the United States and Mexico, and proved that it can address worrying virus variants, paving the way for the approval of another vaccine to control the pandemic.

This company in Maryland– 33 years later, A product that has not yet been approved-indicating that its vaccine provides 100% protection against moderate and severe Covid-19. All Covid-19 cases in the vaccination group are mild.

The two doses of the vaccine showed 93% efficacy for the variants of interest and the emerging variants of interest, which represents the vast majority of cases. It is 91% effective for high-risk groups, such as those over 65 years of age and those with underlying diseases.

Stanley Erck, Novavax’s chief executive officer, stated that the vaccine manufacturer is now “closer” to “addressing the critical and continuing need for additional Covid-19 vaccines in global public health”.

“Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well-known and proven platform, to a world that still needs vaccines,” he said.

The company uses traditional methods to produce vaccines, but grows proteins in moth cells to quickly scale up, and then puts them into nanoparticles. This antigen that teaches the body to recognize the spike protein is enhanced by a proprietary adjuvant.

The trial data of nearly 30,000 participants in the United States and Mexico are similar to the results published by Novavax in previous trials in the United Kingdom and South Africa.Then it found The vaccine is 96% effective The original strain against SARS CoV-2.

However, the vaccine is significantly less effective against the Beta variant that first appeared in South Africa. Last week, Novavax stated that a vaccine tailored to this variant triggered an immune response. Animal and human research Fighting Beta and other strains may pave the way for its use as a booster.

Although test data from outside the United States was released in March, the company has not yet completed its regulatory submission and encountered production issues that delayed its plans. The company said on Monday that it needs to meet chemical, manufacturing and control requirements.

Novavax received $1.6 billion from Operation Warp Speed ​​to fund the production of 100 million doses. The British government agreed to purchase 60 million doses of the vaccine. As part of the agreement, Novavax will produce key components of the vaccine in Stockton Tees.

The vaccine has also been shown to be safe in trials in the United States and Mexico, with almost no serious adverse events, and it is balanced between the participants who received the vaccine and those who took the placebo. As with many vaccines, the most common side effects are fatigue, headaches and muscle pain.



Source link

Recommended For You

About the Author: Agnes Zang